Apimeds Pharmaceuticals US, Inc. (APUS)
| Market Cap | 21.28M |
| Revenue (ttm) | n/a |
| Net Income | n/a |
| EPS | n/a |
| Shares Out | 15.09M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 13,431 |
| Open | 1.350 |
| Previous Close | 1.360 |
| Day's Range | 1.350 - 1.490 |
| 52-Week Range | 0.951 - 5.970 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 26, 2026 |
About APUS
Apimeds Pharmaceuticals US, Inc. provides digital asset treasury solutions in bitcoin treasury infrastructure. The company was incorporated in 2020 and is based in Matawan, New Jersey. Apimeds Pharmaceuticals US, Inc. operates as a subsidiary of Inscobee., Inc.
Financial Performance
Financial StatementsNews
Apimeds Pharmaceuticals US Settles with Inscobee; Merger Proceeds, $100 Million PIPE Financing to Close, and Lōkahi Therapeutics to Advance Apitox Program
MATAWAN, N.J. & LA JOLLA, Calif.--(BUSINESS WIRE)--Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) today announced a comprehensive settlement with Inscobee Inc. and Apimeds Inc. (the “Inscobee ...
Apimeds Pharmaceuticals US Annual report: Q4 2025
Apimeds Pharmaceuticals US has published its Q4 2025 annual report on May 4, 2026.
Inscobee, Apimeds Korea deliver action by written consent to remove directors
Inscobee and Apimeds announced that Inscobee and Apimeds Korea, together with other stockholders of Apimeds Pharmaceuticals (APUS), who beneficially own at least 66% of the voting power of the company...
Apimeds Pharma US reports material breach of merger agreement by Inscobee
MindWave Innovations, a wholly owned subsidiary of Apimeds Pharmaceuticals (APUS) US, announced that on March 20, Inscobee and its wholly owned subsidiary Apimeds, in concert with certain other stockh...
Apimeds Pharmaceuticals US Inc. Announces Material Breach of Merger Agreement by Inscobee Inc. (KS:006490) and Apimeds Inc.; Prepares Filing Emergency Action in Delaware Court of Chancery
MATAWAN, N.J. & SEOUL, South Korea--(BUSINESS WIRE)--MindWave Innovations Inc., a Delaware corporation and wholly owned subsidiary of Apimeds Pharmaceuticals US, Inc. (“APUS” or the “Company”) (NYSE A...
Apimeds Pharmaceuticals confirms FDA Type C meeting for osteoarthritis candidate
Apimeds Pharmaceuticals (APUS) and Lundefinedkahi Therapeutics announced that the FDA Division of Anesthesiology, Addiction Medicine and Pain Medicine, or DAAP, has confirmed a Type C meeting to discu...
Apimeds Pharmaceuticals and Lōkahi Therapeutics Announce FDA Type C Meeting Scheduled for LT‑100 (Apitox)
MATAWAN, N.J. & LA JOLLA, Calif.--(BUSINESS WIRE)--Apimeds Pharmaceuticals US, Inc. and Lōkahi Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) Division of Anesthesi...
Apimeds Pharmaceuticals and MindWave Innovations Announce Closing of $100MM PIPE Financing and Activation of 1,000 Bitcoin to Power AI-Driven Yield Generation Strategy
MATAWAN, N.J.--(BUSINESS WIRE)--Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) today announced the closing of its previously announced $100 million private investment in public equity (PIPE) f...
Apimeds Pharmaceuticals US Inc trading resumes
09:50 EST Apimeds Pharmaceuticals (APUS) US Inc trading resumes
Apimeds Pharmaceuticals, MindWave Innovations announce merger
Apimeds Pharmaceuticals (APUS) announced that it has merged with MindWave Innovations. Apimeds and MindWave signed the merger agreement outlining the terms of the merger, thus paving the way for a…
Apimeds and MindWave Announce Merger, Integrating Biotech Growth with AI-Driven Digital Treasury Yield Generation Backed by $100M PIPE
MATAWAN, N.J.--(BUSINESS WIRE)--(NYSE American: APUS) Apimeds Pharmaceuticals US, Inc. (“Apimeds”), a clinical-stage biotechnology company that completed its IPO in May 2025, today announced that it h...
Apimeds Pharmaceuticals US Inc trading halted, news pending
09:03 EST Apimeds Pharmaceuticals (APUS) US Inc trading halted, news pending
Apimeds Pharmaceuticals US Quarterly report: Q3 2025
Apimeds Pharmaceuticals US has published its Q3 2025 quarterly earnings report on November 12, 2025.
Apimeds Brings ai² Futures Lab™ to the Palouse — Partnering with the University of Idaho to Shape the Future of Biotech Innovation
MATAWAN, N.J. & MOSCOW, Idaho--(BUSINESS WIRE)--Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) (“Apimeds”) today announced the expansion of its ai² Futures Lab™ program through a new collabora...
Apimeds Pharmaceuticals expands AI Futures Lab program
Apimeds Pharmaceuticals (APUS) announced the expansion of the Apimeds AI Futures Lab program through a new collaboration with the University of Oregon’s Lundquist College of Business, starting with th...
Apimeds Pharmaceuticals says “I love my Ducks” with new ai² Futures Lab™ Program collaboration with the University of Oregon's Lundquist College of Business
MATAWAN, N.J. & EUGENE, Ore.--(BUSINESS WIRE)--Apimeds Pharmaceuticals US, Inc. (NYSE: APUS) (“Apimeds”) today announced the expansion of the Apimeds ai² Futures Lab program through a new collaboratio...
Apimeds Expands ai² Future Labs Program to Include University of San Diego Students in Biotech Business Development
MATAWAN, N.J.--(BUSINESS WIRE)--Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) (“Apimeds”) today announced the expansion of its ai² Future Labs program by engaging graduate students from the U...
Apimeds Pharmaceuticals issues statement on FDA draft guidance for pain program
Apimeds Pharmaceuticals (APUS) welcomed the FDA’s newly released draft guidance on the development of non-opioid pain therapies, highlighting its potential to accelerate the company’s lead program, Ap...
Apimeds Welcomes FDA Draft Guidance as Catalyst for Advancing Apitox Non-Opioid Pain Program
MATAWAN, N.J.--(BUSINESS WIRE)--Apimeds Pharmaceuticals US, Inc. (NYSE: APUS) today welcomed the U.S. Food and Drug Administration's (FDA) newly released draft guidance on the development of non-opioi...
Apimeds Pharmaceuticals US, Inc. Partners with University of Alabama to Advance Biotech Business Development via ai² Future Labs
MATAWAN, N.J.--(BUSINESS WIRE)--Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) (“Apimeds”) today announced the launch of its ai² Future Labs program in partnership with The University of Alaba...
Apimeds Expands Leadership Team with Dr. Susan Kramer to Lead Product Development and Brian Peters to Lead its ai² Division
MATAWAN, N.J.--(BUSINESS WIRE)--Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) (“Apimeds” or the “Company”), a clinical-stage biopharmaceutical company developing Apitox, an intradermally admi...
Apimeds Pharmaceuticals US Slides: Corporate Presentation
Apimeds Pharmaceuticals US has posted slides in relation to its latest quarterly earnings report, which was published on July 15, 2025.
Apimeds Pharmaceuticals US, Inc. Announces Closing of Initial Public Offering
Hopewell, New Jersey, May 12, 2025 (GLOBE NEWSWIRE) -- Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) (“Apimeds” or the “Company”), a clinical stage biopharmaceutical company that is in the pr...
Apimeds Pharmaceuticals US, Inc. Announces Pricing of Initial Public Offering
Hopewell, New Jersey, May 08, 2025 (GLOBE NEWSWIRE) -- Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) (“Apimeds” or the “Company”), a clinical stage biopharmaceutical company that is in the pr...